AssetMark Inc
MACK

AssetMark Inc’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

AssetMark Inc’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25
Closed -$2K – 517
2014
Q4 		$2K Buy
+25
New +$1.82K ﹤0.01% 463

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

AssetMark Inc's MACK Position: Q1 2015 in Review

AssetMark Inc sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2015, closing a stake of 25 shares — an estimated $2K sold.

AssetMark Inc first reported a position in MACK in Q4 2014 and held it in 1 quarter. The position peaked at $2K in Q4 2014. 152 funds tracked by Wall St. Rank hold MACK as of Q1 2015.

  • AssetMark Inc reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • AssetMark Inc sold 25 Merrimack Pharmaceuticals, Inc. shares in Q1 2015, an estimated $2K.
  • AssetMark Inc first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • AssetMark Inc's Merrimack Pharmaceuticals, Inc. position peaked at $2K in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2015.

Based on AssetMark Inc's 13F filing for Q1 2015, filed 12 May 2015.